Valuation: Tsubota Laboratory Incorporated

Market Cap 644.86Cr 4.09Cr 3.66Cr 3.39Cr 3.07Cr 5.74Cr 389.39Cr 5.83Cr 41Cr 16Cr 203.67Cr 15Cr 15Cr P/E 2025
49.7x
P/E 2026 -9.95x
Enterprise Value 554.76Cr 3.52Cr 3.15Cr 2.91Cr 2.64Cr 4.94Cr 334.99Cr 5.02Cr 35Cr 14Cr 175.21Cr 13Cr 13Cr EV / Sales 2025
6.38x
EV / Sales 2026 33.4x
Free-Float
28.38%
Yield 2025 *
-
Yield 2026 -
12/08 Tsubota Laboratory Incorporated Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
17/06 Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
01/06 Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
01/06 Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million. CI
15/05 Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026 CI
15/05 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
13/02 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
13/02 Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
12/25/12 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
17/25/17 Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
20/24/20 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
19/22/19 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
20/22/20 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
1 day-0.80%
1 week-4.98%
Current month-1.59%
1 month-3.12%
3 months+2.06%
6 months-15.93%
Current year-27.06%
1 week 246
Extreme 246
263
1 month 242
Extreme 242
285
Current year 210
Extreme 210
478
1 year 210
Extreme 210
478
3 years 210
Extreme 210
625
5 years 210
Extreme 210
1,447
10 years 210
Extreme 210
1,447
Manager TitleAgeSince
President 71 01/02/2019
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 01/01/2025
Director TitleAgeSince
Director/Board Member 71 01/02/2019
Director/Board Member 70 01/06/2020
Director/Board Member 55 01/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
15/11/24 Others

Founder

63,000 0.2465%
15/11/24 Others

Founder

4,20,000 1.6434%
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%-4.98%-27.06%-41.37% 4.09Cr
+0.88%-0.34%+40.64%+73.05% 6.53TCr
-0.77%-0.77%+8.95%+76.11% 5.46TCr
-0.61%+0.64%+8.71%+99.94% 5.36TCr
+0.75%+5.99%+30.57%+57.77% 4.5TCr
-3.24%-7.22%+13.09%+109.29% 4.22TCr
-0.91%-6.90%+215.56%+883.32% 3.94TCr
-2.26%-4.14%+15.38%+45.53% 3.27TCr
-2.70%-10.77%+19.80%-6.47% 2.4TCr
+0.13%+13.95%+58.56%+47.73% 2.65TCr
Average -1.01%+1.65%+38.42%+134.49% 3.83TCr
Weighted average by Cap. -0.82%+2.27%+43.21%+153.66%

Financials

2025 2026
Net sales 135.7Cr 86.13L 77.01L 71.25L 64.51L 1.21Cr 82Cr 1.23Cr 8.57Cr 3.39Cr 43Cr 3.23Cr 3.16Cr 20Cr 12.69L 11.35L 10.5L 10L 17.8L 12Cr 18.09L 1.26Cr 49.99L 6.32Cr 47.64L 46.62L
Net income 20Cr 13.01L 11.63L 10.76L 10L 18.24L 12Cr 18.54L 1.3Cr 51.24L 6.47Cr 48.83L 47.79L -76Cr -48.3L -43.19L -39.96L -36.18L -67.71L -46Cr -68.82L -4.81Cr -1.9Cr -24Cr -1.81Cr -1.77Cr
Net Debt -144.8Cr -91.9L -82.18L -76.03L -68.84L -1.29Cr -87Cr -1.31Cr -9.15Cr -3.62Cr -46Cr -3.45Cr -3.38Cr -90Cr -57.18L -51.13L -47.31L -42.83L -80.17L -54Cr -81.48L -5.69Cr -2.25Cr -28Cr -2.15Cr -2.1Cr
Projected Income Statement - Annual - Tsubota Laboratory Incorporated
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
-
Date Price Change Volume
27/26/27 JP¥248.00 -0.80% 10,300
26/26/26 JP¥250.00 -0.40% 6,400
23/26/23 JP¥251.00 -1.95% 73,500
22/26/22 JP¥256.00 -1.54% 27,700
21/26/21 JP¥260.00 -0.38% 15,300
  1. Stock Market
  2. Stocks
  3. 4890 Stock